After a poor start to the day the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has rebounded strongly and finds itself up 0.4% to 5,771 points in early afternoon trade.
Four shares which have done a lot of the heavy lifting today are listed below. Here’s why they have bolted higher:
The Ardent Leisure Group (ASX: AAD) share price has climbed almost 4% to $1.61 after the entertainment company provided an update on its theme park division. Although revenue and visitor numbers in February were down compared to the prior corresponding period, they were a big improvement on December and January.
The Creso Pharma Ltd (ASX: CPH) share price has rocketed 23% to 47.5 cents after the medical marijuana company announced that it had signed a letter of intent with high-tech Swiss food and pharma development company Domaco. The company expects it to fast-track the commercialisation of its new human and animal health cannabinoid-rich nutraceutical products.
The Impedimed Limited (ASX: IPD) share price has jumped 3% to 71 cents after the medical technology company announced the placement of the first SOZO unit at Scripps Health. The device will be used in an initial study for monitoring patients with chronic heart failure in a clinical setting, in order to provide real-world data.
The Mesoblast limited (ASX: MSB) share price has surged higher by over 4% to $1.87 after the company advised that the U.S. FDA had granted a fast track designation for its MSC-100-IV cell therapy in children with acute Graft Versus Host Disease. The fast track designation has the potential to shorten the time to FDA approval through priority review. Whilst it is still early days, the initial trials have been positive.
Missed out on gains today? Don't worry, I think these growth shares could explode this year.
For many, blue chip stocks means stability, profitability and regular dividends, often full franked..
But knowing which blue chips to buy, and when, can often be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
If you’re expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you’ll be sorely disappointed. Not only are their dividends growing at a snail’s pace, their profits are under pressure too due to the increasing competitive environment.
The contrast to these “new breed” blue chips couldn’t be greater… especially the very real prospect of significant share price gains, something that’s looking less likely from the usual blue chip suspects.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.